stay updated with our newsletter

Subscribe
Facebook Twitter Linkedin

Blood Mycotoxin Testing: Evidence, Limitations, and Interpretation

Everybody is exposed to mold. But as clinicians, how do we know if a patient’s symptoms are caused by mold and/or their associated mycotoxins? As we hear more about the dangers of mycotoxins from water-damaged buildings and the related illnesses they can cause, we must educate ourselves on scientifically supported clinical protocols and approaches. Testing exists, but which has the strongest support? We’ll explore blood mycotoxin testing and review the existing evidence for IgG and IgE antibodies.

Mold and Mycotoxin Exposure

Molds such as Penicillium, Stachybotrys, Fusarium, Aspergillus, and Alternaria produce spores, and spores carry secondary metabolites called mycotoxins, frequently found in water-damaged indoor environments and foods. Mold fragments, spores, and mycotoxins can cause pathology.

Larger than the mycotoxins they produce, molds are 2-3 microns in size compared to mycotoxins, which are 0.1 microns.1 A HEPA filter removes mold spores, but mycotoxins are small enough to pass through. Because of the smaller size, mycotoxins are more accessible to tissues, giving them the opportunity to cause damage.

Mycotoxin exposure occurs through inhalation, dermal absorption, and ingestion. Mycotoxin exposure that causes illness occurs mainly by inhalation from water-damaged buildings and large amounts of ingested mycotoxins.

Inhaled mold from water-damaged buildings poses the greatest concern. Inhaled mycotoxins often bypass this first-pass metabolism, leading to direct interaction with and provocation of the immune system and central nervous system. Small amounts of ingested mycotoxins from foods are primarily detoxified in the liver and gastrointestinal tract. However, a large amount of ingested mycotoxin can damage the gut lining, which can also provoke an immune response. Food sources of mycotoxins include cereals, wheat- and corn-based products, dried fruits, grapes, wine, certain spices, coffee, cocoa, and dairy.2-5

Many mycotoxins exert their toxic effects via multiple mechanisms, including inhibition of protein synthesis and mitochondrial function, oxidative stress, DNA and RNA damage, apoptosis/necrosis, and cell cycle arrest. These damaging mechanisms result in mycotoxins being carcinogenic, teratogenic, hepatotoxic, neurotoxic, and immunotoxic.6-8

Inflammatory responses cause much of the mold-associated pathology.7 The central nervous system, immune system, and respiratory system are primarily affected. The nervous system is one of the first areas affected by mycotoxins, as they cross the blood-brain barrier, leading to neurotoxicity.1

Molds and mycotoxins have immunomodulatory effects, manifesting as allergies, autoimmune disease, and immunosuppression, creating increased susceptibility to pathogenic infections.5,8-11 Molds can cause allergies, resulting in asthma or rhinitis, typical of immediate type 1 hypersensitivity reactions.7,12 Mycotoxin stimulation of IgE antibodies can lead to Mast Cell Activation Syndrome (MCAS).1,13

When to Consider Mycotoxin Testing

The number of buildings with biotoxin infestations is on the rise, and indoor mold sampling methods are not well validated or standardized.14 If a patient has been exposed to a water-damaged building, blood mycotoxin testing should be considered, especially if they present with the following symptoms or conditions:1,7,12,15

  • Headache
  • Fatigue
  • Memory loss
  • Blurred vision
  • Cognitive deficits
  • Loss of balance
  • Nausea
  • Painful lymph nodes
  • Rashes
  • Nosebleeds
  • Shortness of breath/ asthma
  • Rhinitis
  • MCAS
  • Alzheimer’s disease
  • Parkinson’s disease
  • Meniere’s disease
  • Myalgic encephalomyelitis/chronic fatigue syndrome
  • Multiple sclerosis (MS)
  • Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Autism spectrum disorders
  • Autoimmune conditions
  • Local pain syndrome complexes

Even if a possible mycotoxin exposure is unknown, testing should be considered for these conditions, especially if other causes have been ruled out.

What Type of Testing Is Best for Mycotoxins?

Mycotoxin Panels

Testing a panel of mycotoxins is important because individual mold species typically produce several mycotoxins, rather than only one. The same mycotoxin can be produced by multiple different species.16 For example, a panel testing 14 mycotoxins can therefore give information on hundreds of molds.

Direct Mycotoxin Measurements Versus Mycotoxin Antibodies

For decades, monitoring mycotoxins in blood and urine has been used in population-level studies, which generally demonstrate correlations between exposure and measured biological levels.17 However, additional clinical research is needed to determine whether mycotoxin concentrations function as reliable biomarkers for specific disease states. While it is possible to quantify toxin levels in biological samples, translating those measurements into clinically meaningful information requires well-established reference ranges and data linking concentrations to clinical outcomes or adverse effects.16

In contrast to assessing mycotoxin concentrations, IgG and IgE antibodies to mycotoxins in the blood detect the body’s immune response to the mold or mycotoxin. Antibodies to mycotoxins can form adducts that attach to tissues, triggering autoimmunity. IgE antibodies indicate current mast cell stimulation, which can present as classic allergy symptoms or can lead to MCAS. IgG antibodies indicate current exposure to mycotoxins.1,13 IgG responses can vary from immune tolerance to commensal fungi in the body versus pathogenic stimulation from environmental fungi/molds.18

Other Testing

The Shoemaker Protocol® assesses several nonspecific markers (i.e., melanocyte-stimulating hormone, vascular endothelial growth factor [VEGF], C4a, etc.) to evaluate chronic inflammatory response syndrome (CIRS). A specific biomarker pattern may be seen in patients exposed to water-damaged buildings. The laboratory testing does not involve mycotoxin measurement, but rather markers indicating multisystem dysfunction.19 The markers are nonspecific for mold and mycotoxins, as there are many other causes for abnormalities. This protocol requires specific training for practitioner certification.

Test Validity

When questioning a test’s validity, you must consider both analytical and clinical validity. Clinical Laboratory Improvement Amendments (CLIA) certification ensures analytical validity. Commercial labs in the U.S. are required to be CLIA-certified, meaning the lab meets applicable quality and analytical standards to ensure accurate test results. However, CLIA regulations do not address clinical validity, which connects lab results to disease.20 Clinical validity is often established in the literature.

Blood Versus Urine Mycotoxin Testing

Most mycotoxins present in food are below the Tolerable Daily Intake established by health organizations and are rapidly excreted in urine. As a result, urinary mycotoxin levels primarily reflect recent dietary intake and cannot reliably distinguish exposure from contaminated food versus water-damaged buildings.1

Epidemiologic monitoring by regulatory agencies largely focuses on food-related exposure, and data on how inhalational exposure from indoor mold affects urinary levels are limited. In contrast, studies have found higher levels of blood antibodies to molds and mycotoxins in patients exposed to water-damaged buildings compared with healthy controls.12,21

Clinical Validity of Urine Versus Blood Mycotoxin Levels

Urine is commonly used for human biomonitoring because collection is convenient and urinary levels correlate with recent exposure.16,22 However, exposure does not necessarily indicate disease. As mentioned above, low levels of mycotoxins are commonly detected in foods and, therefore, in the urine of healthy individuals without adverse health effects. Some studies even report exposures above accepted daily intake levels without clinical harm.23-28 Elevated urinary levels may simply reflect effective detoxification rather than toxicity, while low levels could indicate poor elimination rather than absence of exposure. High-quality studies linking urinary mycotoxin levels to specific diseases remain limited. Blood measurements may therefore provide a better assessment of overall body burden.1 Studies utilizing blood antibody–based mycotoxin testing have begun to establish clinical correlations.

Exposure Time Frame Differences

Urine testing also reflects only short-term exposure and is subject to daily variability, whereas blood may better represent longer-term exposure.15,23,29-31 Animal toxicokinetic studies suggest that most mycotoxins are eliminated through the kidneys within about 48 hours.23,30 Some mycotoxins have half-lives of only a few hours, meaning exposure may be missed depending on the timing of sampling. If urine testing is used, 24-hour collections are preferred over spot samples, though many laboratories offer only spot testing.16

Serum IgE or IgG levels may be a more reliable index of long-term exposure.15 Fungal IgG antibodies may persist beyond the initial exposure event and may reflect the immune system’s long-term response.18

Federal Agency Recommendations

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) do not recognize urine mycotoxin testing for clinical diagnosis. Available tests have not undergone FDA validation for diagnostic use, and methods vary widely between laboratories in terms of cutoffs, methodologies, and interpretation. No established urinary thresholds indicate harmful exposure, and a positive result does not necessarily signify disease. Federal agencies caution that such testing may lead to misinformation, unnecessary anxiety, incorrect diagnoses, and unwarranted medical interventions.20

Studies Supporting Blood Mycotoxin Testing

A study on 119 patients connected neural autoantibodies and neurophysiologic abnormalities to mold exposure. Patients had proven mold exposure in their homes and/or workplaces, which was verified with mold-specific serum antibody tests to Stachybotrys chartarum, Penicillium, Aspergillus, Cladosporium, Alternaria, and Chaetomium. Patients had symptoms of peripheral neuropathy (e.g., tingling, tremors, loss of sensation in extremities). Peripheral nerve conduction studies and antibodies to 9 neural antigens were tested. All patients had significant increases in neural autoantibodies, and 99 patients had abnormal nerve conduction velocities. This study connects mold exposure to neurological damage.32

In an observational pilot study in autistic patients, both urine and serum were analyzed for mycotoxins in 52 patients and 58 healthy controls. A significant finding was that serum levels of ochratoxin A (OTA), a highly toxic mycotoxin produced by Aspergillus and Penicillum molds, were higher in autistic patients than in controls, whereas urine levels were similar. Average mycotoxin values tended to be lower in the autistic group, suggesting altered detoxification and metabolism of the toxins. This study shows a possible role of OTA in the pathophysiology of autism.33 A separate study on 25 autistic children and 29 controls found no association between urinary mycotoxin exposure and autism.34

Healthy control subjects can have elevated mold and mycotoxin antibodies, indicating widespread exposure of the general population to indoor molds. Studies are mixed, although some show that symptomatic patients tend to have significantly higher levels of certain antibodies in comparison to healthy controls.12,18,35 Test results should always be reviewed in a clinical context.

What Mycotoxins Are Tested in Blood?

The Enzyme-Linked Immunosorbent Assay (ELISA) method detects antibodies to mycotoxin antigens, has excellent accuracy, precision, and specificity, and has been validated and used in several studies.12,30,36 Testing for both IgG and IgE antibodies to the most relevant, disease-causing mycotoxins helps determine long-term exposure and immune activation.15

Common mycotoxins found in water-damaged buildings and contaminated foods that are important to test for in blood include:

  • Ochratoxin A (OTA) and B (OTB): produced by Aspergillus and Penicillium species; immunosuppressive, carcinogenic, teratogenic, nephrotoxic, hepatotoxic;6,31,37-39 99.8% of ochratoxin is tightly bound to albumin and is not easily excreted through the kidneys. It has a half-life in blood of 35 days and is therefore best measured in blood, not urine.16,23,31
  • Satratoxin: a trichothecene mycotoxin mainly produced by Stachybotrys (“black mold”); neurotoxic, fatigue, headaches, nosebleeds, pulmonary hemorrhage, chest pain, dermatitis.40,41
  • T-2 toxin: trichothecene mycotoxin causing diarrhea, vomiting, intestinal hemorrhage, fertility issues.42,43
  • Vomitoxin (Deoxynivalenol): trichothecene mycotoxin that can destroy intestinal barrier function, causing anorexia, inflammatory bowel disease, and celiac disease; reproductive toxin, immunotoxic.44-46
  • Verrucarin and verrucarol: trichothecene mycotoxins mainly produced by Fusarium and Aspergillus species; tremors, immunotoxic, inflammatory.
  • Fumonisin B1: produced by Fusarium molds; hepatotoxic, nephrotoxic, esophageal cancer, depression, mitochondrial dysregulation.39
  • Zearalenone: produced by Fusarium species; hepatotoxic, immunotoxic, xenoestrogen that binds to estrogen receptors, leading to hormonal imbalance, fertility issues, and possible risk for hormonal cancers.47
  • Penicillium Toxin (Mycophenolic acid): immunosuppressive.48
  • Alternaria Toxin (Alternariol): cytotoxic, mutagenic, genotoxic, immunosuppressive.46,49
  • Aspergillus Toxin (Aspergillus hemolysin): immunosuppressive, hemolytic.50
  • Stachybotrys Toxin (Trichothecene): increased vascular fragility, pulmonary hemorrhage, tremors, headaches, seizures, sleep disturbance, incoordination, depression, nerve demyelination, vomiting, diarrhea, hepatotoxicity, intestinal hemorrhage, anorexia, intestinal permeability, rash, photosensitization, skin sloughing, decreased testosterone, increased estrogen.40,51,52
  • Cladosporium HSP 70: neurotoxic, headaches, seizures, sleepiness.
  • Aspergillus auto-toxin (Sterigmatocystin): carcinogenic, mutagenic, teratogenic, hepatotoxic.53
  • Aspergillus/Penicillium Neuro Auto-Toxin (Gliotoxin): immunosuppressive, neurotoxic (linked to MS and others), genotoxic, cytotoxic.8,54
  • Aflatoxin, a potent mycotoxin, is rarely detected in samples of people living in developed countries with access to safer food.16,55 This is a reason it may not be included on blood panels.
→ More information about individual mycotoxins and their effects can be found in this article.

Important Takeaways About Mycotoxin Testing

Navigating toxin-related illnesses, particularly those involving mold exposure and mycotoxins, can feel overwhelming. However, the availability of evidence-based testing methods provides a clearer path forward. By understanding the range of laboratory assessments, clinicians can make more informed clinical decisions, differentiate between exposure and illness, and develop targeted treatment plans.

Remember:

  • Always correlate test results clinically.
  • Urine mycotoxin levels reflect recent exposure (around 48 hours) and may represent healthy clearance/elimination. Literature on clinical correlation with disease is sparse.
  • While additional studies are needed, blood mycotoxin antibody levels represent a promising biomarker with clinical correlation to disease.

References

  1. Campbell AW, Weinstock LB. Molds, Mycotoxins, the Brain, the Gut and Misconceptions. Alternative Therapies in Health and Medicine. 2022;28(3):8-12.
  2. Harding CF, Pytte CL, Page KG, et al. Mold inhalation causes innate immune activation, neural, cognitive and emotional dysfunction. Brain, Behavior, and Immunity. 2020;87:218-228.
  3. Li K, Wang S, Qu W, et al. Natural products for Gut-X axis: pharmacology, toxicology and microbiology in mycotoxin-caused diseases. Frontiers in Pharmacology. 2024;15:1419844.
  4. Ammann HM. Inhalation exposure and toxic effects of mycotoxins. Biology of Microfungi. Springer; 2016:495-523.
  5. Kraft S, Buchenauer L, Polte T. Mold, Mycotoxins and a Dysregulated Immune System: A Combination of Concern? International Journal of Molecular Sciences. 2021;22(22).
  6. Kőszegi T, Poór M. Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level. Toxins. 2016;8(4):111.
  7. Viljoen M, Claassen N. Pathophysiological aspects of exposure to dampness-associated indoor mould and mycotoxins: A mini-overview. Journal of Hazardous Materials Advances. 2023;9:100228.
  8. Ye W, Liu T, Zhang W, Zhang W. The Toxic Mechanism of Gliotoxins and Biosynthetic Strategies for Toxicity Prevention. International Journal of Molecular Sciences. 2021;22(24).
  9. Antonissen G, Martel A, Pasmans F, et al. The impact of Fusarium mycotoxins on human and animal host susceptibility to infectious diseases. Toxins. 2014;6(2):430-452.
  10. Sun Y, Song Y, Long M, Yang S. Immunotoxicity of Three Environmental Mycotoxins and Their Risks of Increasing Pathogen Infections. Toxins. 2023;15(3).
  11. Sun Y, Huang K, Long M, Yang S, Zhang Y. An update on immunotoxicity and mechanisms of action of six environmental mycotoxins. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association. 2022;163:112895.
  12. Vojdani A, Campbell AW, Kashanian A, Vojdani E. Antibodies against molds and mycotoxins following exposure to toxigenic fungi in a water-damaged building. Archives of Environmental Health. 2003;58(6):324-336.
  13. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders? Expert Review of Clinical Immunology. 2019;15(6):639-656.
  14. Saghir SA, Bancroft J, Ansari R. Molds and mycotoxins indoors I: Current issues and way forward. In. Vol 7: ProBiologists; 2024:1-7.
  15. Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clinical Therapeutics. 2018;40(6):903-917.
  16. Cramer B, Visintin L, Maris E, et al. Human biomonitoring of mycotoxins: key challenges and future directions. Mycotoxin Research. 2025;42(1):13.
  17. Escrivá L, Font G, Manyes L, Berrada H. Studies on the Presence of Mycotoxins in Biological Samples: An Overview. Toxins. 2017;9(8).
  18. Diez-Martin E, Hernandez-Suarez L, Astigarraga E, Ramirez-Garcia A, Barreda-Gómez G. Mycobiota and Antifungal Antibodies as Emerging Targets for the Diagnosis and Prognosis of Human Diseases. Journal of Fungi (Basel, Switzerland). 2025;11(4).
  19. Dooley M, Vukelic A, Jim L. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery (2012). 2024;86(12):7248-7254.
  20. Kawamoto M, Page E. Notes from the field: Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness–United States, 2014. MMWR Morbidity and Mortality Weekly Report. 2015;64(6):157-158.
  21. Vojdani A, Thrasher JD, Madison RA, Gray MR, Heuser G, Campbell AW. Antibodies to molds and satratoxin in individuals exposed in water-damaged buildings. Archives of Environmental Health. 2003;58(7):421-432.
  22. Franco LT, Petta T, Rottinghaus GE, et al. Assessment of mycotoxin exposure and risk characterization using occurrence data in foods and urinary biomarkers in Brazil. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association. 2019;128:21-34.
  23. Heyndrickx E, Sioen I, Huybrechts B, Callebaut A, De Henauw S, De Saeger S. Human biomonitoring of multiple mycotoxins in the Belgian population: Results of the BIOMYCO study. Environment International. 2015;84:82-89.
  24. Gerding J, Cramer B, Humpf HU. Determination of mycotoxin exposure in Germany using an LC-MS/MS multibiomarker approach. Molecular Nutrition & Food Research. 2014;58(12):2358-2368.
  25. Rodríguez-Carrasco Y, Moltó JC, Mañes J, Berrada H. Exposure assessment approach through mycotoxin/creatinine ratio evaluation in urine by GC-MS/MS. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association. 2014;72:69-75.
  26. Escrivá L, Manyes L, Font G, Berrada H. Mycotoxin Analysis of Human Urine by LC-MS/MS: A Comparative Extraction Study. Toxins. 2017;9(10).
  27. Wells L, Hardie L, Williams C, et al. Deoxynivalenol Biomarkers in the Urine of UK Vegetarians. Toxins. 2017;9(7).
  28. Li C, Deng C, Zhou S, et al. High-throughput and sensitive determination of urinary zearalenone and metabolites by UPLC-MS/MS and its application to a human exposure study. Anal Bioanal Chem. 2018;410(21):5301-5312.
  29. Alvito P, Pereira-da-Silva L. Mycotoxin Exposure during the First 1000 Days of Life and Its Impact on Children’s Health: A Clinical Overview. Toxins. 2022;14(3).
  30. Garg K, Villavicencio-Aguilar F, Solano-Rivera F, Gilbert L. Analytical Validation of a Direct Competitive ELISA for Multiple Mycotoxin Detection in Human Serum. Toxins. 2022;14(11).
  31. Malir F, Ostry V, Pfohl-Leszkowicz A, Malir J, Toman J. Ochratoxin A: 50 Years of Research. Toxins. 2016;8(7).
  32. Campbell AW, Thrasher JD, Madison RA, Vojdani A, Gray MR, Johnson A. Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds in water-damaged buildings. Archives of Environmental Health. 2003;58(8):464-474.
  33. De Santis B, Brera C, Mezzelani A, et al. Role of mycotoxins in the pathobiology of autism: A first evidence. Nutritional Neuroscience. 2019;22(2):132-144.
  34. Duringer J, Fombonne E, Craig M. No Association between Mycotoxin Exposure and Autism: A Pilot Case-Control Study in School-Aged Children. Toxins. 2016;8(7).
  35. Edmondson DA, Barrios CS, Brasel TL, Straus DC, Kurup VP, Fink JN. Immune response among patients exposed to molds. International Journal of Molecular Sciences. 2009;10(12):5471-5484.
  36. Erkekoğlu P, Sabuncuoğlu S, Aydin S, Sahin G, Giray B. Determination of seasonal variations in serum ochratoxin A levels in healthy population living in some regions of Turkey by enzyme-linked immunosorbent assay. Toxicon: Official Journal of the International Society on Toxinology. 2010;55(2-3):507-513.
  37. Mubarik Y, Boyetey ST, Aikins AR, Mutocheluh M. Effect of Ochratoxin A (OTA) on the Immune System: A Systematic Review. Toxins. 2025;17(5).
  38. Ou Y, Fu Q, Chen Y, et al. Dietary Ochratoxin A Contamination Modulates Oxidative Stress, Inflammation Processes and Causes Fibrosis in in vitro and in vivo Lung Models. Frontiers in Bioscience (Landmark edition). 2023;28(2):22.
  39. Omotayo OP, Omotayo AO, Mwanza M, Babalola OO. Prevalence of Mycotoxins and Their Consequences on Human Health. Toxicological Research. 2019;35(1):1-7.
  40. Dyląg M, Spychała K, Zielinski J, Łagowski D, Gnat S. Update on Stachybotrys chartarum-Black Mold Perceived as Toxigenic and Potentially Pathogenic to Humans. Biology. 2022;11(3).
  41. Brasel TL, Douglas DR, Wilson SC, Straus DC. Detection of airborne Stachybotrys chartarum macrocyclic trichothecene mycotoxins on particulates smaller than conidia. Applied and Environmental Microbiology. 2005;71(1):114-122.
  42. Zhang S, Song W, Hua Z, et al. Overview of T-2 Toxin Enterotoxicity: From Toxic Mechanisms and Detoxification to Future Perspectives. Journal of Agricultural and Food Chemistry. 2024;72(7):3314-3324.
  43. Yang X, Liu P, Cui Y, et al. Review of the Reproductive Toxicity of T-2 Toxin. Journal of Agricultural and Food Chemistry. 2020;68(3):727-734.
  44. Akbari P, Braber S, Gremmels H, et al. Deoxynivalenol: a trigger for intestinal integrity breakdown. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2014;28(6):2414-2429.
  45. Gomes A, Fernandes GSA, Bracarense A. Deoxynivalenol and male reproductive toxicity: Unraveling the hidden risks. Toxicology. 2025;516:154191.
  46. Gufler J, Heffeter P, Kowol CR, Hager S, Marko D. Opposing effects of mycotoxins alternariol and deoxynivalenol on the immunomodulatory effects of oxaliplatin and triapine. Toxicology. 2025;511:154039.
  47. Rogowska A, Pomastowski P, Sagandykova G, Buszewski B. Zearalenone and its metabolites: Effect on human health, metabolism and neutralisation methods. Toxicon: Official Journal of the International Society on Toxinology. 2019;162:46-56.
  48. Vaali K, Tuomela M, Mannerström M, Heinonen T, Tuuminen T. Toxic Indoor Air Is a Potential Risk of Causing Immuno Suppression and Morbidity-A Pilot Study. Journal of Fungi (Basel, Switzerland). 2022;8(2).
  49. Solhaug A, Eriksen GS, Holme JA. Mechanisms of Action and Toxicity of the Mycotoxin Alternariol: A Review. Basic & Clinical Pharmacology & Toxicology. 2016;119(6):533-539.
  50. Fukuchi Y, Kudo Y, Kumagai T, Ebina K, Yokota K. Oxidized low density lipoprotein inhibits the hemolytic activity of Asp-hemolysin from Aspergillus fumigatus. FEMS Microbiology Letters. 1998;167(2):275-280.
  51. Pestka JJ, Yike I, Dearborn DG, Ward MD, Harkema JR. Stachybotrys chartarum, trichothecene mycotoxins, and damp building-related illness: new insights into a public health enigma. Toxicological Sciences: An official Journal of the Society of Toxicology. 2008;104(1):4-26.
  52. Hossain MA, Ahmed MS, Ghannoum MA. Attributes of Stachybotrys chartarum and its association with human disease. The Journal of Allergy and Clinical Immunology. 2004;113(2):200-208; quiz 209.
  53. Díaz Nieto CH, Granero AM, Zon MA, Fernández H. Sterigmatocystin: A mycotoxin to be seriously considered. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association. 2018;118:460-470.
  54. Purzycki CB, Shain DH. Fungal toxins and multiple sclerosis: A compelling connection. Brain Research Bulletin. 2010;82(1-2):4-6.
  55. Krausová M, Ayeni KI, Gu Y, et al. Longitudinal biomonitoring of mycotoxin exposure during pregnancy in the Yale Pregnancy Outcome Prediction Study. Environment International. 2024;194:109081.

 

Related Articles